ATS bankruptcy
This article was originally published in The Gray Sheet
Executive Summary
Smith & Nephew will gain full control of the Dermagraft tissue-engineered dermal replacement product joint venture with Advanced Tissue Sciences via a proposed purchase of ATS' stake for $12 mil. ATS, which filed for Chapter 11 protection Oct. 10 in southern California federal bankruptcy court, expects to be advanced up to $5 mil. of the purchase price to continue operations until the sale is approved by the court. In addition to Dermagraft for diabetic foot ulcers, the deal includes TransCyte temporary skin cover for serious burns; combined sales are expected to reach $8 mil. this year, S&N says. Upon completion of the deal, S&N will become a contract manufacturer for non-wound care products retained by ATS. The companies will dissolve their NeoCyte human cartilage development joint venture...
You may also be interested in...
TriVex, Dyonics Launches To Spur 2003 Endoscopy Sales, S&N Predicts
Smith & Nephew is attributing declining sales of its BoneCutter disposable arthroscopy blade sales in the first half of 2003 to increased reuse of the products following the enactment of the Medical Device User Fee & Modernization Act
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.